Gastrointestinal Stromal Tumor Gist clinical trials

Explore recruiting gastrointestinal stromal tumor gist clinical trials.

Recruiting gastrointestinal stromal tumor gist studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Gastrointestinal Stromal Tumor Gist trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Master Protocol for the Multi-Cohort, Phase 1/2 Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies

Portugal, Netherlands, Denmark, Spain, Italy, Germany +2 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

ATEZOGIST – A prospective, randomized, multicenter, comparative study of the efficacy of imatinib resumption combined with atezolizumab versus imatinib resumption alone in patients with unresectable advanced gastrointestinal stromal tumors (GIST) after failure of standard treatments

France

Therapeutic exploratory (Phase II) EU CTIS Study details

An International, Phase 3, Randomized, Multicenter, Open-label Study of Ripretinib vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumor (GIST) with KIT Exon 11 and Co-occurring KIT Exons 17 and/or 18 Mutations Who Were Previously Treated with Imatinib (INSIGHT)

Norway, France, Germany, Netherlands, Spain, Poland +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-Label, Multicenter, First-in-Human, Phase 1 Dose Escalation and Multicohort Expansion Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors, Including Sarcomas.

France, Italy, Netherlands, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Gastrointestinal Stromal Tumor Gist trials by city

Gastrointestinal Stromal Tumor Gist in Toronto Gastrointestinal Stromal Tumor Gist in Vancouver Gastrointestinal Stromal Tumor Gist in Montreal Gastrointestinal Stromal Tumor Gist in Calgary Gastrointestinal Stromal Tumor Gist in Edmonton Gastrointestinal Stromal Tumor Gist in Ottawa Gastrointestinal Stromal Tumor Gist in Winnipeg Gastrointestinal Stromal Tumor Gist in Quebec City Gastrointestinal Stromal Tumor Gist in Hamilton Gastrointestinal Stromal Tumor Gist in Kitchener Gastrointestinal Stromal Tumor Gist in London Gastrointestinal Stromal Tumor Gist in Halifax Gastrointestinal Stromal Tumor Gist in New York Gastrointestinal Stromal Tumor Gist in Los Angeles Gastrointestinal Stromal Tumor Gist in Chicago Gastrointestinal Stromal Tumor Gist in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease